Home > Boards > US Listed > Biotechs > MultiCell Technologies (MCET)

With a multi-billion dollar oncology drug, Multicell Technologies

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
TPX Member Profile
Member Level 
Followed By 540
Posts 35,774
Boards Moderated 6
Alias Born 10/24/13
160x600 placeholder
TPX Member Level  Monday, 09/24/18 10:10:55 AM
Re: MyDogBuster post# 43227
Post # of 43268 
With a multi-billion dollar oncology drug, Multicell Technologies will also make a great profit!

Multicell Immunotherapeutics, Inc.: 75000 shares Selling Stockholder of GTBP Gt Biopharma Inc.

The date of this prospectus supplement is September 21, 2018.

Settlement Agreement

On September 8, 2018, we entered into a Confidential Settlement Agreement and Release, or the Settlement Agreement, with Multicell Immunotherapeutics, Inc., or Multicell, to settle a breach of contract lawsuit. As part of the Settlement Agreement, we agreed to issue to Multicell 75,000 shares of Common Stock at an agreed value of $2.00 per share. Multicell is a selling stockholder. For purposes of the table below, beneficial ownership is based on the securities held of record by the selling stockholders as of May 11, 2018.


GT Biopharma Inc (OTCMKTS:GTBP) Makes Great Strides In War Against Cancer

The drugs business is very competitive. Firms lack relevance if they do not innovate to avail new products to combat chronic ailments. To that end, GT Biopharma Inc (OTCMKTS:GTBP) commits to continually innovate to fight cancer.

New product trial
In an August 28, 2018 press statement, the biotechnology company announced trial of OXS-1550. The trial incorporates another “multi-billion dollar oncology drug.” The project is a joint initiative with “a major Pharmaceutical Company (the Company).”

According to the statement, Dr. Daniel Vallera will lead the initiative. Per the release, Dr Vallera is Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota.

Commenting on the trial, he said:

“Based on our exciting preliminary in vitro experiments, the initial preclinical work suggests a much greater effect when OXS-1550 is given with this drug. We are very excited about our progress with GT’s OXS-1550 (DT2219) combined with ibrutinib, a potent small molecule Bruton Tyrosine Kinase (BTK) inhibitor which is already an established chemotherapeutic agent. We believe combination therapies like these that kill cancer cells based on entirely different mechanisms are the future of cancer treatment.”

GT Biopharma Inc (OTCMKTS:GTBP) in strategic partnerships
Further, GT Biopharma Inc (OTCMKTS:GTBP) announced advanced stages in the concept behind Natural Killer cell (NK) hypothesis. As part of the efforts to materialize the research, GT Biopharma is working with “colleagues at the Masonic Center.” The partnership aims to facilitate transitioning of “TriKE and TetraKE NK cell-engager platforms” into clinical development. Specifically, GT Biopharma wants the partnership to help on the regulatory requirements.

We have found a handful of Hemp Oil companies that qualify to be all organic and grown in the U.S.A. Here is one of the best all organic CBD oil products on the market. It’s by Greenleaf Farms, I believe you can get up to 30% by visiting them today!

The company’s Chairman and CEO is optimistic regarding the mainstream interest in the NK cell field. In his words, he says:

“I believe that the NK cell field, much like the T-cell field did some years ago, is about to explode onto the scene with rapid advances in both the science and the clinical development spheres. I also believe that GT Biopharma will be leading that charge and bringing to the clinic innovative and formidable new NK cell-engager based therapies.”

The company hopes that the new platforms will facilitate faster adoption of the NK cell field’s principles. As per the CEO, combating contemporary illnesses require groundbreaking innovations.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist